Luis Garcia-Bordes

Luis Garcia-Bordes


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2025 in Journal of Experimental Orthopaedics
Verified
Journal Article
Open access
LGLuis Garcia-Bordes
Luis Garcia-Bordes
PÁPedro Álvarez‐Díaz
Pedro Álvarez‐Díaz
EAEduard Alentorn‐Geli
Eduard Alentorn‐Geli
AFAlfred Ferré‐Aniorte
Alfred Ferré‐Aniorte
PLPatricia Laiz‐Boada
Patricia Laiz‐Boada
RCRamon Cugat‐Bertomeu
Ramon Cugat‐Bertomeu
Purpose: The purpose of this study is to describe the inter‐ and intra‐individual differences in the platelet concentration between blood and platelet‐rich plasma (PRP) preparation, assess intersubject differences considering demographic and anthropometric variables, describe PRP code distribution and analyse intrasubject variability.Methods: A retrospective analysis was conducted using a single‐centre patient database from November 2021 to November 2023. It included patients with musculoskeletal pathologies treated with PRP injections. Primary variables were demographic characteristics (sex, age, body mass index [BMI]) and platelet concentrations in blood and PRP during treatments. Secondary analysis focused on PRP code frequency distribution and intrasubject variability according to different coding systems.Results: Here, 686 patients met the inclusion criteria. PRP exhibited significantly higher platelet concentrations compared to blood (378.01 ± 136.25 × 103 platelets/µL vs. 221.97 ± 58.21 × 103 platelets/µL, p < 0.001). Younger patients had higher platelet concentrations in both blood (p = 0.004) and PRP (p = 0.003), whereas female patients showed higher platelet concentrations only in blood (p < 0.001). The platelet concentration ratio was higher in males (p < 0.001) and those with higher BMI (p = 0.023). Significant differences were found between the existing and modified PRP coding systems (p < 0.001). Intrasubject variability was higher in PRP than in blood (coefficient of variance: 21.32 ± 17.36 in blood vs. 27.85 ± 19.10 in PRP, p < 0.001).Conclusion: Age, gender, BMI and intrasubject variations significantly affect PRP formulation, emphasizing the importance of addressing these variables for a more predictable, personalized and effective therapeutic approach.Level of Evidence: This is a retrospective study. Level IV.

14 July 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
LGLuis Garcia-Bordes
Luis Garcia-Bordes
LELorenzo Escutia
Lorenzo Escutia
SVSilvia Vizcaíno
Silvia Vizcaíno
PLPatricia Laiz
Patricia Laiz
Roberto SeijasRoberto Seijas
Roberto Seijas
RCRamon Cugat
Ramon Cugat
Background/Objectives: The anticoagulant used for blood collection is a fundamental but underexplored variable in platelet-rich plasma (PRP) preparation. Ethylenediaminetetraacetic acid (EDTA) and sodium citrate act on platelets through distinct calcium chelation mechanisms with potentially different consequences for PRP quality. Our group has previously demonstrated that biological and demographic variables independently modulate platelet composition in PRP; the present study extends this analysis to the pre-analytical anticoagulant variable. No prospective paired clinical study has systematically compared the effects of EDTA and sodium citrate on platelet morphological parameters in a real clinical setting. This study aimed to characterise these differences and evaluate their implications for orthobiologic therapy. Methods: A prospective within-subject paired-sample study was conducted at Instituto Cugat—Quirónsalud Barcelona (November 2025–April 2026). Twenty-six consecutive adult patients undergoing routine blood extraction prior to orthopaedic procedures had blood drawn simultaneously into K2-EDTA and sodium citrate (3.2%) tubes. Full haematological analysis was performed on a Sysmex XN automated analyser within 30 min. Primary outcomes were mean platelet volume (MPV), platelet distribution width (PDW), large platelet ratio (P-LCR), large platelet cell count (P-LCC), and plateletcrit (PCT). Statistical comparisons used the paired t-test or Wilcoxon signed-rank test; effect sizes were quantified as Cohen’s d. Results: Seven of eight platelet-related parameters differed significantly between anticoagulants (all p < 0.001). Compared to sodium citrate, EDTA produced systematically higher MPV (+10.1%, d = 2.81), P-LCR (+25.8%, d = 2.41), P-LCC (+24.3%, d = 1.70), PDW (+13.5%, d = 1.33), PCT (+7.3%, d = 0.78), RDW-CV (+2.0%, d = 0.83), and RDW-SD (+2.6%, d = 0.80). MPV was higher with EDTA in all 26/26 paired samples without exception. Total platelet count did not differ significantly (p = 0.135). Effect sizes for all morphological parameters were large (d ≥ 0.78). Conclusions: EDTA is associated with large, reproducible, and universal platelet morphological changes consistent with calcium chelation-induced artefact, not genuine platelet hypertrophy. These artefactual changes systematically overestimate platelet size and large platelet indices by up to 26%, with direct implications for PRP quality assessment in orthobiologic medicine. Sodium citrate should remain the anticoagulant of choice for PRP preparation. Clinicians using EDTA must recognise that morphological parameters do not reflect functional platelet capacity.

18 May 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
LGLuis Garcia-Bordes
Luis Garcia-Bordes
LELorenzo Escutia
Lorenzo Escutia
SVSilvia Vizcaíno
Silvia Vizcaíno
PLPatricia Laiz
Patricia Laiz
Roberto SeijasRoberto Seijas
Roberto Seijas
RCRamon Cugat
Ramon Cugat
Background/Objectives: The anticoagulant used for blood collection is a fundamental but underexplored variable in platelet-rich plasma (PRP) preparation. Ethylenediaminetetraacetic acid (EDTA) and sodium citrate act on platelets through distinct calcium chelation mechanisms with potentially different consequences for PRP quality. Our group has previously demonstrated that biological and demographic variables independently modulate platelet composition in PRP; the present study extends this analysis to the pre-analytical anticoagulant variable. No prospective paired clinical study has systematically compared the effects of EDTA and sodium citrate on platelet morphological parameters in a real clinical setting. This study aimed to characterise these differences and evaluate their implications for orthobiologic therapy. Methods: A prospective within-subject paired-sample study was conducted at Instituto Cugat – Quirónsalud Barcelona (November 2025–April 2026). Twenty-six consecutive adult patients undergoing routine blood extraction prior to orthopaedic procedures had blood drawn simultaneously into K₂-EDTA and sodium citrate (3.2%) tubes. Full haematological analysis was performed on a Sysmex XN automated analyser within 30 minutes. Primary outcomes were mean platelet volume (MPV), platelet distribution width (PDW), large platelet ratio (P-LCR), large platelet cell count (P-LCC), and plateletcrit (PCT). Statistical comparisons used the paired t-test or Wilcoxon signed-rank test; effect sizes were quantified as Cohen's d. Results: Seven of eight platelet-related parameters differed significantly between anticoagulants (all p<0.001). Compared to sodium citrate, EDTA produced systematically higher MPV (+10.1%, d=2.81), P-LCR (+25.8%, d=2.41), P-LCC (+24.3%, d=1.70), PDW (+13.5%, d=1.33), PCT (+7.3%, d=0.78), RDW-CV (+2.0%, d=0.83), and RDW-SD (+2.6%, d=0.80). MPV was higher with EDTA in all 26/26 paired samples without exception. Total platelet count did not differ significantly (p=0.135). Effect sizes for all morphological parameters were large (d≥0.78). Conclusions: EDTA induces large, reproducible, and universal platelet morphological changes consistent with calcium chelation-induced swelling, not genuine platelet hypertrophy. These artefactual changes systematically overestimate platelet size and large platelet indices by up to 26%, with direct implications for PRP quality assessment in orthobiologic medicine. Sodium citrate should remain the anticoagulant of choice for PRP preparation. Clinicians using EDTA must recognise that morphological parameters do not reflect functional platelet capacity.

1 June 2026 in EFORT Open Reviews
Verified
Journal Article
Open access
PDF file
LGLuis Garcia-Bordes
Luis Garcia-Bordes
RVRoberto Seijas Vázquez
Roberto Seijas Vázquez
PDPedro Álvarez Díaz
Pedro Álvarez Díaz
AEAnna Castelló Egea
Anna Castelló Egea
XSXavier Cuscó Segarra
Xavier Cuscó Segarra
RBRamón Cugat Bertomeu
Ramón Cugat Bertomeu
Intraosseous platelet-rich plasma (IO-PRP) therapy is an emerging biologic approach targeting the osteochondral unit in osteoarthritis (OA), especially of the knee and hip, by addressing subchondral bone pathology implicated in disease progression. This review synthesizes clinical and preclinical evidence on IO-PRP from PubMed and Scopus (up to May 2025), focusing on its biological rationale, therapeutic efficacy, and applications in osteoarticular disease. Evidence from randomized trials, observational studies, and experimental models indicates that IO-PRP – particularly when combined with intra-articular PRP – improves pain, function, and joint structure in moderate-to-severe OA. Preclinical studies demonstrate IO-PRP’s role in subchondral bone remodelling, mesenchymal stromal cell modulation, and inflammation reduction, supporting its disease-modifying potential. IO-PRP represents a promising, biologically grounded intervention for OA management; however, further standardized, long-term clinical trials are needed to determine optimal protocols and validate long-term benefits.

12 May 2026 in Arthroscopy Techniques
Verified
Journal Article
Open access
PDF file
LGLuis Garcia-Bordes
Luis Garcia-Bordes
XSXavier Cuscó Segarra
Xavier Cuscó Segarra
PDPedro Álvarez Díaz
Pedro Álvarez Díaz
RVRoberto Seijas Vázquez
Roberto Seijas Vázquez
DBDavid Barastegui
David Barastegui
RBRamón Cugat Bertomeu
Ramón Cugat Bertomeu
Lateral hinge fracture is a frequent complication of medial opening‐wedge high tibial osteotomy. Previous strategies—such as inserting an additional third Kirschner wire (K‐wire) from the lateral tibial cortex—reinforce the lateral cortex but do not address the potential fracture line that propagates proximally toward the tibial plateau and joint surface. We describe a simple maneuver that reuses the 2 K‐wires routinely employed to guide the osteotomy plane. Once the osteotomy cut is complete, the wires are withdrawn and reinserted horizontally into the proximal metaphyseal tibia, just above the osteotomy gap. Acting as a temporary metaphyseal block, the wires stabilize the epiphyseal‐metaphyseal unit and limit upward fracture propagation into the joint during gradual gap opening. This simple technique is cost‐neutral, reproducible, and complements existing hinge‐protection methods by specifically protecting the articular extension pathway.